Global Initiatives

Posted: April 2017 By Cynthia L. Kryder, MS, CCC-Sp, with Ramón Rami-Porta, MD Clinicians around the world began implementing the 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer on January 1, 2017. There has been confusion, however, over when the 8th edition of the TNM staging system will be fully…

Posted: February 2017 By Chee-Keong Toh, MD, and Daniel SW Tan, MD The recent decade has seen much interest in lung cancer in never-smokers (LCNS), in most part attributed to the expanding number of therapeutically tractable alterations enriched within this clinical phenotype.1 However, equally relevant are studies directed at understanding the etiology of LCNS, for…

By Julien Mazières, MD, PhD, and Julie Milia, PhD Once considered a “man’s disease,” lung cancer no longer discriminates. During the last decade, lung cancer in women has become the most common cause of cancer death in women in the US, surpassing breast cancer, and the second leading cause of cancer death in women in…

By Jyoti Malhotra, MD, MPH and Paolo Boffetta, MD, MPH Lung cancer is the most frequent malignant neoplasm in most countries worldwide, and the main cause of cancer death in both sexes.1,2 As per GLOBOCAN, lung cancer accounted for an estimated 1,242,000 new cases among men, which is 17% of all cancers excluding non-melanoma skin…

Posted: November 1, 2016 How one investigator’s passion and devotion to science led to discovery of the “ghost gene” in MPM Q&A with Michele Carbone, MD Q: Many laboratories are now working on the link between BAP1 and mesothelioma. How did you come up with the idea that there was genetic susceptibility to developing mesothelioma?…

By Cynthia L. Kryder, MS IASLC Lung Cancer News recently spoke with Kapil Dhingra, MD, of KAPital Consulting LLC in Sparta, New Jersey, about oncologic drug development and the challenges and opportunities to anticipate in the future. Q: What are the perils and pitfalls of oncologic drug development in the new millennium? A: I don’t…

Next-generation sequencing (NGS) technology has revolutionized genomic and genetic research as it fulfills its potential to tailor the treatment of cancer patients in general and non-small cell lung cancer (NSCLC) patients in particular to their cancer genome alterations. The role of NGS in drug development and clinical trials varies worldwide in response to regional and…

By Adi F. Gazdar, MD While all of the major histological forms of lung cancer are strongly associated with smoking, an important subset (about 20% worldwide, 10–15% in the US) arise in lifetime never-smokers. Lung cancer in never-smokers (LCNS) targets the female gender, East Asian ethnicity, and adenocarcinoma histology. 1 While environmental smoke exposure (ESE),…

By Cynthia L. Kryder, MS Roswell Park Cancer Institute in Buffalo, New York, US, expects to be the site for the first US clinical trial of CimaVax, the groundbreaking lung cancer vaccine developed at Cuba’s Center for Molecular Immunology (CIM). Set to commence within the next 6 months, pending clearance from the FDA, the trial…